Literature DB >> 31169548

Implications of juvenile idiopathic arthritis genetic risk variants for disease pathogenesis and classification.

Peter A Nigrovic1,2, Marta Martínez-Bonet1,3, Susan D Thompson4.   

Abstract

PURPOSE OF REVIEW: We assess the implications of recent advances in the genetics of juvenile idiopathic arthritis (JIA) for the evolving understanding of inflammatory arthritis in children. RECENT
FINDINGS: JIA exhibits prominent genetic associations with the human leukocyte antigen (HLA) region, extending perhaps surprisingly even to the hyperinflammatory systemic JIA category. Some HLA associations resemble those for adult-onset inflammatory arthritides, providing evidence for pathogenic continuity across the age spectrum. Genome-wide association studies have defined an increasing number of JIA-linked non-HLA loci, many again shared with adult-onset arthritis. As most risk loci contain only noncoding variants, new experimental methods such as SNP-seq and innovative big-data strategies help identify responsible causative mutations, termed functional SNPs (fSNPs). Alternately, gene hunting in multiplex families implicates new genes in monogenic childhood arthritis, including MYD88 and the intriguing innate immune gene LACC1.
SUMMARY: Genetic data indicate a continuity between JIA and adult arthritis poorly reflected in current nomenclature. Advancing methodologies will help to identify new pathogenic mechanisms that inform the understanding of biologic subdivisions within JIA. Resulting insights will facilitate the application of lessons learned across the age spectrum to the treatment of arthritis in children and adults.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31169548      PMCID: PMC6800096          DOI: 10.1097/BOR.0000000000000637

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  58 in total

1.  International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Authors:  Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

Review 2.  Decoding enhancers using massively parallel reporter assays.

Authors:  Fumitaka Inoue; Nadav Ahituv
Journal:  Genomics       Date:  2015-06-10       Impact factor: 5.736

3.  Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects.

Authors:  Jill A Hollenbach; Susan D Thompson; Teodorica L Bugawan; Mary Ryan; Marc Sudman; Miranda Marion; Carl D Langefeld; Glenys Thomson; Henry A Erlich; David N Glass
Journal:  Arthritis Rheum       Date:  2010-06

4.  Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus.

Authors:  Alberto Martini; Angelo Ravelli; Tadej Avcin; Michael W Beresford; Ruben Burgos-Vargas; Ruben Cuttica; Norman T Ilowite; Raju Khubchandani; Ronald M Laxer; Daniel J Lovell; Ross E Petty; Carol A Wallace; Nico M Wulffraat; Angela Pistorio; Nicolino Ruperto
Journal:  J Rheumatol       Date:  2018-10-01       Impact factor: 4.666

5.  Genotypic variability based association identifies novel non-additive loci DHCR7 and IRF4 in sero-negative rheumatoid arthritis.

Authors:  Wen-Hua Wei; Sebastien Viatte; Tony R Merriman; Anne Barton; Jane Worthington
Journal:  Sci Rep       Date:  2017-07-13       Impact factor: 4.379

6.  Human LACC1 increases innate receptor-induced responses and a LACC1 disease-risk variant modulates these outcomes.

Authors:  Amit Lahiri; Matija Hedl; Jie Yan; Clara Abraham
Journal:  Nat Commun       Date:  2017-06-08       Impact factor: 14.919

Review 7.  Neutrophil Heterogeneity as Therapeutic Opportunity in Immune-Mediated Disease.

Authors:  Ricardo Grieshaber-Bouyer; Peter A Nigrovic
Journal:  Front Immunol       Date:  2019-03-04       Impact factor: 7.561

8.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Authors:  Luke Jostins; Stephan Ripke; Rinse K Weersma; Richard H Duerr; Dermot P McGovern; Ken Y Hui; James C Lee; L Philip Schumm; Yashoda Sharma; Carl A Anderson; Jonah Essers; Mitja Mitrovic; Kaida Ning; Isabelle Cleynen; Emilie Theatre; Sarah L Spain; Soumya Raychaudhuri; Philippe Goyette; Zhi Wei; Clara Abraham; Jean-Paul Achkar; Tariq Ahmad; Leila Amininejad; Ashwin N Ananthakrishnan; Vibeke Andersen; Jane M Andrews; Leonard Baidoo; Tobias Balschun; Peter A Bampton; Alain Bitton; Gabrielle Boucher; Stephan Brand; Carsten Büning; Ariella Cohain; Sven Cichon; Mauro D'Amato; Dirk De Jong; Kathy L Devaney; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Lynnette R Ferguson; Denis Franchimont; Karin Fransen; Richard Gearry; Michel Georges; Christian Gieger; Jürgen Glas; Talin Haritunians; Ailsa Hart; Chris Hawkey; Matija Hedl; Xinli Hu; Tom H Karlsen; Limas Kupcinskas; Subra Kugathasan; Anna Latiano; Debby Laukens; Ian C Lawrance; Charlie W Lees; Edouard Louis; Gillian Mahy; John Mansfield; Angharad R Morgan; Craig Mowat; William Newman; Orazio Palmieri; Cyriel Y Ponsioen; Uros Potocnik; Natalie J Prescott; Miguel Regueiro; Jerome I Rotter; Richard K Russell; Jeremy D Sanderson; Miquel Sans; Jack Satsangi; Stefan Schreiber; Lisa A Simms; Jurgita Sventoraityte; Stephan R Targan; Kent D Taylor; Mark Tremelling; Hein W Verspaget; Martine De Vos; Cisca Wijmenga; David C Wilson; Juliane Winkelmann; Ramnik J Xavier; Sebastian Zeissig; Bin Zhang; Clarence K Zhang; Hongyu Zhao; Mark S Silverberg; Vito Annese; Hakon Hakonarson; Steven R Brant; Graham Radford-Smith; Christopher G Mathew; John D Rioux; Eric E Schadt; Mark J Daly; Andre Franke; Miles Parkes; Severine Vermeire; Jeffrey C Barrett; Judy H Cho
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

9.  Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes.

Authors:  Harm-Jan Westra; Marta Martínez-Bonet; Suna Onengut-Gumuscu; Annette Lee; Yang Luo; Nikola Teslovich; Jane Worthington; Javier Martin; Tom Huizinga; Lars Klareskog; Solbritt Rantapaa-Dahlqvist; Wei-Min Chen; Aaron Quinlan; John A Todd; Steve Eyre; Peter A Nigrovic; Peter K Gregersen; Stephen S Rich; Soumya Raychaudhuri
Journal:  Nat Genet       Date:  2018-09-17       Impact factor: 41.307

10.  Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications.

Authors:  Michael J Ombrello; Victoria L Arthur; Elaine F Remmers; Anne Hinks; Ioanna Tachmazidou; Alexei A Grom; Dirk Foell; Alberto Martini; Marco Gattorno; Seza Özen; Sampath Prahalad; Andrew S Zeft; John F Bohnsack; Norman T Ilowite; Elizabeth D Mellins; Ricardo Russo; Claudio Len; Maria Odete E Hilario; Sheila Oliveira; Rae S M Yeung; Alan M Rosenberg; Lucy R Wedderburn; Jordi Anton; Johannes-Peter Haas; Angela Rosen-Wolff; Kirsten Minden; Klaus Tenbrock; Erkan Demirkaya; Joanna Cobb; Elizabeth Baskin; Sara Signa; Emily Shuldiner; Richard H Duerr; Jean-Paul Achkar; M Ilyas Kamboh; Kenneth M Kaufman; Leah C Kottyan; Dalila Pinto; Stephen W Scherer; Marta E Alarcón-Riquelme; Elisa Docampo; Xavier Estivill; Ahmet Gül; Carl D Langefeld; Susan Thompson; Eleftheria Zeggini; Daniel L Kastner; Patricia Woo; Wendy Thomson
Journal:  Ann Rheum Dis       Date:  2016-12-07       Impact factor: 19.103

View more
  10 in total

Review 1.  The Challenges and Opportunities of Classifying Childhood Arthritis.

Authors:  Dax G Rumsey; Ronald M Laxer
Journal:  Curr Rheumatol Rep       Date:  2020-01-11       Impact factor: 4.592

2.  Implications of Evolving Disease Classification for Drug Approval in Juvenile Idiopathic Arthritis.

Authors:  Siobhan M Case; Peter A Nigrovic
Journal:  Paediatr Drugs       Date:  2022-04-01       Impact factor: 3.022

Review 3.  Genetic overlap between type 1 diabetes and other autoimmune diseases.

Authors:  Ana Márquez; Javier Martín
Journal:  Semin Immunopathol       Date:  2021-10-01       Impact factor: 9.623

Review 4.  Juvenile idiopathic arthritis.

Authors:  Alberto Martini; Daniel J Lovell; Salvatore Albani; Hermine I Brunner; Kimme L Hyrich; Susan D Thompson; Nicolino Ruperto
Journal:  Nat Rev Dis Primers       Date:  2022-01-27       Impact factor: 65.038

Review 5.  Biological classification of childhood arthritis: roadmap to a molecular nomenclature.

Authors:  Peter A Nigrovic; Robert A Colbert; V Michael Holers; Seza Ozen; Nicolino Ruperto; Susan D Thompson; Lucy R Wedderburn; Rae S M Yeung; Alberto Martini
Journal:  Nat Rev Rheumatol       Date:  2021-03-17       Impact factor: 20.543

Review 6.  Recent progress in the treatment of non-systemic juvenile idiopathic arthritis.

Authors:  John M Bridges; Elizabeth D Mellins; Randy Q Cron
Journal:  Fac Rev       Date:  2021-02-26

7.  Systemic Juvenile Idiopathic Arthritis/Pediatric Still's Disease, a Syndrome but Several Clinical Forms: Recent Therapeutic Approaches.

Authors:  Pierre Quartier
Journal:  J Clin Med       Date:  2022-03-01       Impact factor: 4.241

Review 8.  How does age determine the development of human immune-mediated arthritis?

Authors:  Yannick Degboe; Sebastiaan J Vastert; Berent J Prakken; Iain B McInnes
Journal:  Nat Rev Rheumatol       Date:  2022-08-10       Impact factor: 32.286

9.  Analysis of chromatin data supports a role for CD14+ monocytes/macrophages in mediating genetic risk for juvenile idiopathic arthritis.

Authors:  Elizabeth A Crinzi; Emma K Haley; Kerry E Poppenberg; Kaiyu Jiang; Vincent M Tutino; James N Jarvis
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

10.  Gut microbiota in children with juvenile idiopathic arthritis: characteristics, biomarker identification, and usefulness in clinical prediction.

Authors:  Xubo Qian; Yong-Xin Liu; Xiaohong Ye; Wenjie Zheng; Shaoxia Lv; Miaojun Mo; Jinjing Lin; Wenqin Wang; Weihan Wang; Xianning Zhang; Meiping Lu
Journal:  BMC Genomics       Date:  2020-04-07       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.